You are here » Home » Companies » Company Overview » Syngene International Ltd

Syngene International Ltd.

BSE: 539268 Sector: Health care
NSE: SYNGENE ISIN Code: INE398R01022
BSE 00:00 | 24 Apr Syngene International Ltd
NSE 05:30 | 01 Jan Syngene International Ltd
OPEN 311.45
PREVIOUS CLOSE 313.35
VOLUME 5726
52-Week high 368.10
52-Week low 201.65
P/E 36.34
Mkt Cap.(Rs cr) 12,268
Buy Price 305.10
Buy Qty 2.00
Sell Price 315.00
Sell Qty 100.00
OPEN 311.45
CLOSE 313.35
VOLUME 5726
52-Week high 368.10
52-Week low 201.65
P/E 36.34
Mkt Cap.(Rs cr) 12,268
Buy Price 305.10
Buy Qty 2.00
Sell Price 315.00
Sell Qty 100.00

Syngene International Ltd. (SYNGENE) - Chairman Speech

Company chairman speech

MESSAGE TO SHAREHOLDERS

Dear Shareholders

As we endeavour to add value in research and innovation for our partners and customerswe are focusing on executing a strategy of differentiated services by expanding andstrengthening our current range of capabilities.

FY18 delivered a strong performance for Syngene driven by an expansion of our clientbase as well an enhancement of our dedicated centres.

Through a combination of competency and capability building over the years we havecreated sustainable value and laid a solid foundation for our long-term growth.

The global contract research industry continues to become ever more dynamic withclients demanding not only the traditional range of high-quality cost competitiveservices but are increasingly looking for more sophisticated fully integrated researchsolutions often delivered through a strategic partnership model. In meeting the needs ofthis growing and diverse customer group Syngene continues to move up the R&D valuechain transitioning from providing simple cost-arbitrage based offerings to complexfully integrated services that deliver enhanced R&D innovation with greaterefficiency and at an operating cost that ensures real value creation.

Syngene with its deep scientific capabilities fiexible business models focus onoperating efficiency and strong track record of service excellence offers much to itsclients.

Technology is increasingly playing a disruptive role in redefining the way R&D isconducted. Advancements in data science automation and artificial intelligence has madeit possible to sift through large volumes of genetic and other multiplexed research andclinical data to figure out how biology works and why diseases happen. The ability to readand edit DNA is improving rapidly. The latest data analytics tools are helping gain betterinsights and make useful predictions about what new approaches will and won’t workthus enabling faster and better decision making. Syngene’s growing capability in thisarea positions us well to support clients in the longer term. The rapid pace of innovationwithin biology is poised to bring further transformational change within healthcare acrossthe world. In this context it was particularly pleasing to see the strong growth withinour Discovery Biology business bolstered with the commissioning of our state of the artsingle-use bioreactor biologics manufacturing facility. The combined strength we now havein Discovery Biology and in Biologics Manufacturing augurs well for the future and allowsus to offer high end services in one of the fastest growing areas of the industry. Thebreadth of Syngene’s’ scientific capabilities stretch beyond the core clientindustries of pharmaceuticals and biotechnology and are now gaining increasing relevancein other adjacent industry groups like speciality chemicals food and nutrition cosmeticsas well as agri-tech.

Changing consumer behavior increased awareness about health and hygiene rising incomeand changes in life style are altering the dynamics of industries as diverse aspharmaceuticals food and nutrition cosmetics consumer goods and animal health. All ofthese industries are seeing increasing demand for newer products and breakthroughinnovation.

To cater to this demand companies are both increasing their own investments in R&Dbut also looking to tap into the deep scientific knowledge and experience withinCRO’s like Syngene to stay ahead of the curve. This trend continues to offer furtheravenues for growth through outsourcing and collaborating as an external partner to thesecompanies.

All this is bringing about a paradigm change in the contract research space. Providingintegrated services across multiple domains simultaneously driving innovation efficiencyand a superior customer experience is playing a central role in redefining therelationship between a client and their outsourcing partner. When outsourcing complexscience it is evident that effective collaboration transparent communication and theability to operate as a trusted partner become key determinants of the success of anycollaboration.

Syngene with its deep scientific capabilities fiexible business models focus onoperating efficiency and strong track record of service excellence offers much to itsclients. We have earned a reputation for our ability to consistently deliver advancedservices accelerate time-to-market for client projects lower operating costs and helpour clients improve the ROI of their R&D investments. Syngene has evolved to become atrusted long term strategic partner for many of our clients. Our responsiveness agilityand adaptability to change have been central to achieving this position and are the sourceof our ability to create value to our clients.

FY18 was another good year for Syngene. During the year our revenues grew by 17%EBITDA by 10% and PAT increased by 6%. We continued to closely engage with our clients toget a deeper insight into their evolving R&D requirements to ensure we continue toalign our strategies to meet their emerging needs. We strengthened our collaborations withexisting clients and also added many new leading global players in the life and non-lifesciences space to our clientele. We expanded our geographical presence with the openingof a US subsidiary to enable us to be ever closer our US based clients. Through the yearwe have been fortunate to win various awards and accolades from both national andinternational certification bodies. These serve as a testament to the high standards withwhich we operate and refiect the hard work and dedication seen across the thousands ofstaff at Syngene.

As we move forward into FY19 I would like to express my sincere gratitude to my fellowDirectors for their commitment and professionalism in paving Syngene’s long-termpath. My deep appreciation to all our loyal and valuable shareholders for their continuedconfidence and support. My thanks to our suppliers and lenders who continue to be ourpartners in growth. Lastly our management team and staff for their valuable and ongoingdedication over the past year in contributing to Syngene’s growth.

Thank you

Kiran Mazumdar Shaw